Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia

American Journal of Cardiology

Volumn 107, Issue 7, 2011, Pages

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Okopien, Bogusaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; FENOFIBRATE; GAMMA INTERFERON; INTERLEUKIN 1BETA; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSLIPIDEMIA; EVENING DOSAGE; FEMALE; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; MONOCYTE; MORNING DOSAGE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 79952746761     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.11.023     Document Type: Article

References (29)

1. M. Pruski, R. Krysiak, and B. Okopien Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia Diabetes Care 32 2009 1421 1424
2. G.K. Hansson Inflammatory mechanisms in atherosclerosis J Thromb Haemost 7 suppl 1 2009 328 331
3. C.M. Weyand, B.R. Younge, and J.J. Goronzy T cells in arteritis and atherosclerosis Curr Opin Lipidol 19 2008 469 477
4. H.M. Wilson, R.N. Barker, and L.P. Erwig Macrophages: promising targets for the treatment of atherosclerosis Curr Vasc Pharmacol 7 2009 234 243
5. N. Kher, and J.D. Marsh Pathobiology of atherosclerosisa brief review Semin Thromb Hemost 30 2004 665 672
6. A. Tedgui, and Z. Mallat Cytokines in atherosclerosis: pathogenic and regulatory pathways Physiol Rev 86 2006 515 581
7. K. Schroecksnadel, B. Frick, C. Winkler, and D. Fuchs Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease Curr Vasc Pharmacol 4 2006 205 213 (Pubitemid 46785488)
8. B. Okopien, R. Krysiak, M. Haberka, and Z.S. Herman Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia J Cardiovasc Pharmacol 45 2005 314 320 (Pubitemid 40411286)
9. B. Okopie, R. Krysiak, J. Kowalski, A. Madej, D. Belowski, M. Zieliski, and Z.S. Herman Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates J Cardiovasc Pharmacol 46 2005 377 386 (Pubitemid 41262842)
10. R. Krysiak, A. Gdula-Dymek, J. Scieszka, and B. Okopien Anti-inflammatory and Monocyte-Suppressing effects of simvastatin in patients with impaired fasting glucose Basic Clin Pharmacol Toxicol 108 2011 131 137
11. B. Okopie, R. Krysiak, J. Kowalski, A. Madej, D. Belowski, M. Zieliski, K. Labuzek, and Z.S. Herman The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia Atherosclerosis 176 2004 327 335 (Pubitemid 39369523)
12. B. Okopie, J. Kowalski, R. Krysiak, K. abuzek, A. Stachura-Kuach, A. Kuach, M. Zieliski, and Z.S. Herman Monocyte suppressing action of fenofibrate Pharmacol Rep 57 2005 367 372 (Pubitemid 41030697)
13. B. Okopien, R. Krysiak, and Z.S. Herman Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance J Clin Endocrinol Metab 91 2006 1770 1778
14. S. Kinlay, and J. Egido Inflammatory biomarkers in stable atherosclerosis Am J Cardiol 98 suppl 2006 2P 8P
15. P.M. Ridker Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity Nutr Rev 65 suppl 2007 S253 S259
16. G.M. Keating, and D. Omrod Micronised fenofibrate An updated review of its clinical efficacy in the management of dyslipidaemia Drugs 62 2002 1909 1944
17. National Cholesterol Education Program Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
18. S.M. Grundy, and L.D.L. Small Atherogenic dyslipidemia, and the metabolic syndrome Circulation 95 1997 1 4
19. D. Kirmizis, A. Papagianni, F. Dogrammatzi, L. Skoura, A.M. Belechri, E. Alexopoulos, G. Efstratiadis, and D. Memmos Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis J Atheroscler Thromb 17 2010 1256 1265
20. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y.A. Kesniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, M. Laakso FIELD Study Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
21. BIP (Bezafibrate Infarction Prevention) Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
22. S. Fazio More clinical lessons from the FIELD study Cardiovasc Drugs Ther 23 2009 235 241
23. R. Paumelle, and B. Staels Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms Trends Cardiovasc Med 18 2008 73 78 (Pubitemid 351626602)
24. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff Jr, W.C. Cushman, D.G. Simons-Morton, R.P. Byington ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
25. J.A. Farmer Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials Curr Diab Rep 8 2008 71 77 (Pubitemid 351384879)
26. G. Martin, H. Duez, C. Blanquart, V. Berezowski, P. Poulain, J.C. Fruchart, J. Najib-Fruchart, C. Glineur, and B. Staels Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I J Clin Invest 107 2001 1423 1432 (Pubitemid 32522036)
27. B. Staels, M. Maes, and A. Zambon Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease Nat Clin Pract Cardiovasc Med 5 2008 542 553
28. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr, J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
29. T. Yamakawa, T. Takano, S. Tanaka, K. Kadonosono, and Y. Terauchi Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus J Atheroscler Thromb 15 2008 269 275